Day: September 21, 2025

health news

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-‘749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Staff September 21, 2025

Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with...

Read MoreRead more about New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-‘749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed
health news

C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting

Staff September 21, 2025

Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response Rate (ORR) at the Highest Dose Level (100 µg) and...

Read MoreRead more about C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting

You may have missed

health news

Atropos Health Expands Oncology Precision Medicine Capabilities with Publication of New AI Algorithms for Rare Disease and Integration of ASCO Guidelines

Staff December 5, 2025
health news

USF and Old Dominion to Play in the 2025 StaffDNA Cure Bowl

Staff December 5, 2025
health news

The Dot Corp Expands Services With New Promotional Products & Apparel Division

Staff December 5, 2025
health news

Vaniam Group Launches Predictive Pathways: A New Capability for Anticipating Market-Shaping Signals

Staff December 5, 2025
health news

Life Sciences BPO Market is expected to generate a revenue of USD 481.8 Billion by 2032, Globally, at 7.50% CAGR: Verified Market Research®

Staff December 5, 2025
error: Content is protected !!